Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent (IC) obtained.~* Histologically confirmed adenocarcinoma of prostate~* Progressive metastatic disease~* Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (LHRH) analogue or antagonist or bilateral orchiectomy~* Adequate bone marrow, hepatic and renal function~* Able to swallow the ODM-201 whole as a capsule or tablet.~Exclusion Criteria:~* Previous chemotherapy for prostate cancer.~* Known metastases in the brain.~* History of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.~* Known gastrointestinal condition that can significantly affect the absorption of the study treatment.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ODM-201 Tablet A (Type: EXPERIMENTAL): ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
- ODM-201 Tablet B (Type: EXPERIMENTAL): ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.

Based on this trial design, predict the completion outcome and termination type (if applicable).